← Back to Search

DASH Diet for High Blood Pressure (DASH4D Trial)

N/A
Waitlist Available
Led By Elizabeth Selvin, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 or older
Diabetes Mellitus Type 2 defined by HbA1c ≥6.5% or treatment of diabetes with diabetes medication(s)
Must not have
Estimated glomerular filtration rate (eGFR) <30 mL/min by either the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation or the simplified Modification of Diet in Renal Disease Study (MDRD) equation
Weight loss or gain of >5.0% of body weight during prior 2 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at the end of 5-week feeding period
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a special diet for people with diabetes and different salt levels to see how they affect blood pressure. It focuses on adults with Type 2 diabetes who have moderately high blood pressure. The goal is to find out if healthier food choices and less salt can help lower their blood pressure.

Who is the study for?
Adults with Type 2 Diabetes and blood pressure between 120-159/under 100 mmHg, who can eat on-site meals regularly, have stable weight, no other clinical trials or severe illnesses. Must not be pregnant or planning pregnancy, without significant dietary restrictions that affect adherence.
What is being tested?
The DASH4D trial is testing the effects of a diabetes-modified DASH diet versus a typical American diet and the impact of low versus high sodium intake on blood pressure in people with Type 2 Diabetes through a controlled feeding study.
What are the potential side effects?
There may not be direct side effects from participating as this trial involves dietary changes rather than medication. However, changes in diet can sometimes cause digestive discomfort or alterations in energy levels.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have Type 2 diabetes with an HbA1c of 6.5% or higher, or I am on diabetes medication.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is severely reduced.
Select...
I have lost or gained more than 5% of my weight in the last 2 months.
Select...
My arm's circumference is at least 50cm.
Select...
I have Type 1 diabetes.
Select...
I have not had any major heart issues or strokes in the last 6 months.
Select...
I visited the ER for asthma or COPD in the past 6 months.
Select...
I have had recent issues with my digestive system, including surgery or inflammation.
Select...
I needed help or was hospitalized for low blood sugar in the past year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at the end of 5-week feeding period
This trial's timeline: 3 weeks for screening, Varies for treatment, and at the end of 5-week feeding period for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Systolic blood pressure (SBP)
Secondary study objectives
Diastolic blood pressure (DBP)
Other study objectives
Cardiovascular disease (CVD) risk percentage
Fasting glucose level
Fructosamine level
+26 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: Comparison diet with higher sodiumExperimental Treatment2 Interventions
Dietary pattern that is typical of what many Americans with diabetes eat, with sodium level of 3700 mg/day
Group II: DASH4D diet with lower sodiumActive Control2 Interventions
DASH-style dietary pattern, modified for people with diabetes, with sodium level of 1500 mg/day
Group III: DASH4D diet with higher sodiumActive Control2 Interventions
DASH-style dietary pattern, modified for people with diabetes, with sodium level of 3700 mg/day
Group IV: Comparison diet with lower sodiumActive Control2 Interventions
Dietary pattern that is typical of what many Americans with diabetes eat, with sodium level of 1500 mg/day

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for high blood pressure include dietary modifications such as the DASH diet, which emphasizes increased intake of fruits, vegetables, and low-fat dairy products while reducing sodium intake. The mechanism of action involves improving nutrient intake, which helps to balance electrolytes and reduce blood volume, thereby lowering blood pressure. Reducing sodium intake specifically decreases fluid retention and vascular resistance, which are key contributors to high blood pressure. These dietary changes are crucial for hypertension patients as they can significantly lower blood pressure, reduce the risk of cardiovascular events, and improve overall heart health.

Find a Location

Who is running the clinical trial?

Sheikh Khalifa Stroke Institute at Johns HopkinsUNKNOWN
University of Colorado - Anschutz Medical CampusUNKNOWN
6 Previous Clinical Trials
1,360 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,444 Previous Clinical Trials
4,331,111 Total Patients Enrolled

Media Library

DASH4D diet Clinical Trial Eligibility Overview. Trial Name: NCT04286555 — N/A
High Blood Pressure Research Study Groups: DASH4D diet with lower sodium, DASH4D diet with higher sodium, Comparison diet with lower sodium, Comparison diet with higher sodium
High Blood Pressure Clinical Trial 2023: DASH4D diet Highlights & Side Effects. Trial Name: NCT04286555 — N/A
DASH4D diet 2023 Treatment Timeline for Medical Study. Trial Name: NCT04286555 — N/A
High Blood Pressure Patient Testimony for trial: Trial Name: NCT04286555 — N/A
~24 spots leftby Nov 2025